Biology Reference
In-Depth Information
[54] Daley GQ, Van Etten RA, Baltimore D. Induction of chronic myelogenous leukemia in
mice by the P210bcr/abl gene of the Philadelphia chromosome. Science 1990;247:
824-30.
[55] Moorman AV, Chilton L, Wilkinson J, Ensor HM, Bown N, Proctor SJ. A popula-
tion-based cytogenetic study of adults with acute lymphoblastic leukemia. Blood
2010;115:206-14.
[56] Shepherd P, Suffolk R, Halsey J, Allan N. Analysis of molecular breakpoint and m-RNA
transcripts in a prospective randomized trial of interferon in chronic myeloid leukae-
mia: no correlation with clinical features, cytogenetic response, duration of chronic
phase, or survival. Br J Haematol 1995;89:546-54.
[57] Buzyn A, Ostankovitch M, Zerbib A, Kemula M, Connan F, Varet B, et al. Peptides
derived from the whole sequence of BCR-ABL bind to several class I molecules allowing
specific induction of human cytotoxic T lymphocytes. Eur J Immunol 1997;27:2066-72.
[58] Bocchia M, Wentworth PA, Southwood S, Sidney J, McGraw K, Scheinberg DA, et al.
Specific binding of leukemia oncogene fusion protein peptides to HLA class I mol-
ecules. Blood 1995;85:2680-4.
[59] Pinilla-Ibarz J, Cathcart K, Korontsvit T, Soignet S, Bocchia M, Caggiano J, et al. Vac-
cination of patients with chronic myelogenous leukemia with bcr-abl oncogene break-
point fusion peptides generates specific immune responses. Blood 2000;95:1781-7.
[60] Pawelec G, Max H, Halder T, Bruserud O, Merl A, da Silva P, et al. BCR/ABL leuke-
mia oncogene fusion peptides selectively bind to certain HLA-DR alleles and can be
recognized by T cells found at low frequency in the repertoire of normal donors. Blood
1996;88:2118-24.
[61] Cathcart K, Pinilla-Ibarz J, Korontsvit T, Schwartz J, Zakhaleva V, Papadopoulos EB,
et al. A multivalent bcr-abl fusion peptide vaccination trial in patients with chronic
myeloid leukemia. Blood 2004;103:1037-42.
[62] Bocchia M, Gentili S, Abruzzese E, Fanelli A, Iuliano F, Tabilio A, et al. Effect of a p210
multipeptide vaccine associated with imatinib or interferon in patients with chronic
myeloid leukaemia and persistent residual disease: a multicentre observational trial.
Lancet 2005;365:657-62.
[63] Rojas JM, Knight K, Wang L, Clark RE. Clinical evaluation of BCR-ABL peptide immuni-
sation in chronic myeloid leukaemia: results of the EPIC study. Leukemia 2007;21:
2287-95.
[64] Rosa DS, Tzelepis F, Cunha MG, Soares IS, Rodrigues MM. The pan HLA DR-binding
epitope improves adjuvant-assisted immunization with a recombinant protein con-
taining a malaria vaccine candidate. Immunol Lett 2004;92:259-68.
[65] Pinilla-Ibarz J, Korontsvit T, Zakhaleva V, Roberts W, Scheinberg DA. Synthetic peptide
analogs derived from bcr/abl fusion proteins and the induction of heteroclitic human
T-cell responses. Haematologica 2005;90:1324-32.
[66] Jain N, Reuben JM, Kantarjian H, Li C, Gao H, Lee BN, et al. Synthetic tumor-specific
breakpoint peptide vaccine in patients with chronic myeloid leukemia and minimal
residual disease: a phase 2 trial. Cancer 2009;115:3924-34.
[67] Rojas JM, Knight K, Watmough S, Bell J, Wang L, Callaghan T, et al. BCR-ABL peptide
vaccination in healthy subjects: Immunological responses are equivalent to those in
chronic myeloid leukaemia patients. Leuk Res 2010;35:369-72.
[68] Grunebach F, Mirakaj V, Muller MR, Brummendorf T, Brossart P. BCR-ABL is not an im-
munodominant antigen in chronic myelogenous leukemia. Cancer Res 2006;66:5892-
900.
[69] Takahashi T, Tanaka Y, Nieda M, Azuma T, Chiba S, Juji T, et al. Dendritic cell vaccina-
tion for patients with chronic myelogenous leukemia. Leuk Res 2003;27:795-802.
[70] Perez A, Kastner P, Sethi S, Lutz Y, Reibel C, Chambon P. PMLRAR homodimers:
distinct DNA binding properties and heteromeric interactions with RXR. EMBO J
1993;12:3171-82.
[71] Grignani F, Valtieri M, Gabbianelli M, Gelmetti V, Botta R, Luchetti L, et al. PML/RAR
alpha fusion protein expression in normal human hematopoietic progenitors dictates
myeloid commitment and the promyelocytic phenotype. Blood 2000;96:1531-7.
[72] Gambacorti-Passerini C, Grignani F, Arienti F, Pandolfi PP, Pelicci PG, Parmiani G. Hu-
man CD4 lymphocytes specifically recognize a peptide representing the fusion region
of the hybrid protein pml/RAR alpha present in acute promyelocytic leukemia cells.
Blood 1993;81:1369-75.
[73] Dermime S, Bertazzoli C, Marchesi E, Ravagnani F, Blaser K, Corneo GM, et al. Lack of
T-cell-mediated recognition of the fusion region of the pml/RAR-alpha hybrid protein by
lymphocytes of acute promyelocytic leukemia patients. Clin Cancer Res 1996;2:593-600.
[74] Cen D, Hu G, Zhou Y, Yang L, Chen S, Schmidt CA, et al. Enhancement of specific cel-
lular immune response induced by DNA vaccines encoding PML-RARalpha and hIL-2
genes. Hematology 2010;15:88-95.
162
Search WWH ::
Custom Search